Midkine as a novel target for antibody therapy in osteosarcoma

Biochemical and Biophysical Research Communications

Volumn 358, Issue 3, 2007, Pages 757-762

  Maehara, Hiroki ^a   Kaname, Tadashi ^a,d   Yanagi, Kumiko ^a   Hanzawa, Hiroaki ^a   Owan, Ichiro ^a   Kinjou, Takao ^a   Kadomatsu, Kenji ^b   Ikematsu, Shinya ^c   Iwamasa, Teruo ^a   Kanaya, Fuminori ^a   Naritomi, Kenji ^a,d  

^a UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MEIJI DAIRIES CORPORATION   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Antibody therapy; Midkine; Osteosarcoma; Prognosis

Indexed keywords

MIDKINE; MIDKINE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL GROWTH; CELL LINE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL RATE; TUMOR CELL;

ADOLESCENT; ADULT; ANTIBODIES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 34249008371     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.183     Document Type: Article

References (15)

1. Longhi A., Errani C., De Paolis M., Mercuri M., and Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 32 (2006) 423-436
2. Tomer G., Cohen I.J., Kidron D., Katz K., Yosipovitch Z., Meller I., and Zaizov R. Prognostic factors in non-metastatic limb osteosarcoma: A 20-year experience of one center. Int. J. Oncol. 15 (1999) 179-185
3. Stokkel M.P., Linthorst M.F., Borm J.J., Taminiau A.H., and Pauwels E.K. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J. Cancer Res. 128 (2002) 393-399
4. Bacci G., Longhi A., Versari M., Mercuri M., Briccoli A., and Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106 (2006) 1154-1161
5. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., Goldhirsch A., Untch M., Mariani G., Baselga J., Kaufmann M., Cameron D., Bell R., Bergh J., Coleman R., Wardley A., Harbeck N., Lopez R.I., Mallmann P., Gelmon K., Wilcken N., Wist E., Rovira P.S., and Piccart-Gebhart M.J. For the HERA study team, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
6. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333 (2005) 328-335
7. Nakagawara A., Milbrandt J., Muramatsu T., Deuel T.F., Zhao H., Cnaan A., and Brodeur G.M. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 55 (1995) 1792-1797
8. Kadomatsu K., and Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204 (2004) 127-143
9. J.T. Kaifi, H.C. Fiegel, S.L. Rafnsdottir, K. Aridome, P.G. Schurr, U. Reichelt, R. Wachowiak, H. Kleinhans, E.F. Yekebas, O. Mann, K. Ichihara-Tanaka, T. Muramatsu, D. Kluth, T. Strate, J.R. Izbicki, Midkine as a prognostic marker for gastrointestinal stromal tumors, J. Cancer Res. Clin. Oncol., in press, doi:10.1007/s00432-006-0180-y.
10. Ikematsu S., Nakagawara A., Nakamura Y., Sakuma S., Wakai K., Muramatsu T., and Kadomatsu K. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br. J. Cancer 88 (2003) 1522-1526
11. Shimada H., Nabeya Y., Tagawa M., Okazumi S., Matsubara H., Kadomatsu K., Muramatsu T., Ikematsu S., Sakuma S., and Ochiai T. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 94 (2003) 628-632
12. Kaname T., Kadomatsu K., Aridome K., Yamashita S., Sakamoto K., Ogawa M., Muramatsu T., and Yamamura K. The expression of truncated MK in human tumors. Biochem. Biophys. Res. Commun. 219 (1996) 256-260
13. Ikematsu S., Yano A., Aridome K., Kikuchi M., Kumai H., Nagano H., Okamoto K., Oda M., Sakuma S., Aikou T., Muramatsu H., Kadomatsu K., and Muramatsu T. Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer 83 (2000) 701-706
14. Miyashiro I., Kaname T., Nakayama T., Nakamori S., Yagyu T., Monden T., Kikkawa N., Nishisho I., Muramatsu T., Monden M., and Akiyama T. Expression of truncated midkine in human colorectal cancers. Cancer Lett. 106 (1996) 287-291
15. Ikematsu S., Okamoto K., Yoshida Y., Oda M., Sugano-Nagano H., Ashida K., Kumai H., Kadomatsu K., Muramatsu H., Muramatsu T., and Sakuma S. High levels of urinary midkine in various cancer patients. Biochem. Biophys. Res. Commun. 306 (2003) 329-332